News and Trends 1 Oct 2025 Merck backs out of Britain: is the U.K. struggling to retain its life sciences sector? Merck’s decision to back out of its $1 billion expansion comes as U.K. investments in life sciences declines. October 1, 2025 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
More News! 6 Jun 2023 $5.5M funding for Oncopole to tackle cancer Oncopole, Fonds de recherche du Québec – Santé (FRQS) cancer division in Canada, has received major investments that boost its public-private partnership model dedicated to the fight against cancer. Oncopole will continue to pursue its mission thanks to a $3 million reinvestment from founding partner Merck Canada. Oncopole, FRQS cancer division, is the result of […] June 6, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Sponsored by Merck 9 May 2023 Separation and analysis of empty and filled capsids during viral vector production May 9, 2023 - 6 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
Podcast 21 Apr 2023Beyond Biotech podcast 42 This week, we’re talking about the upcoming Lund Spring Symposium with Claes Wahlestedt, Leonard M. Miller professor and director of the Center for Therapeutic Innovation (CTI) and associate dean for therapeutic innovation at the University of Miami Miller School of Medicine; about Meet2Win with Lucia Robert, CEO of MATWIN which stages the event; and then […] April 21, 2023 Share WhatsApp Twitter Linkedin Email
Infographics by Merck 28 Mar 2023 Infographic: Why choosing a client-centric CTDMO is critical when outsourcing biomanufacturing projects In 2021, 28% of FDA approvals were granted to biologic drugs, showcasing the increasing demand for the biopharma industry to develop, manufacture and market biologic-based therapies. Biologic drugs include monoclonal antibodies and large molecules produced in mammalian cells, bringing the already complex process of drug development to a new level. Although the biomanufacturing of many […] March 28, 2023 - 2 minutesmins - By Maya Chergova Share WhatsApp Twitter Linkedin Email
In Depth 1 Feb 2023 The future of cancer treatment: Exploiting cancer’s key vulnerabilities By Victoria Zazulina, M.D., head of development unit, oncology, for the healthcare business of Merck Since 2000, February 4 has been recognized as World Cancer Day and marked by efforts across the globe to raise awareness of the disease’s devastating impact and encourage efforts to improve prevention, detection and treatment. Over the past two decades, […] February 1, 2023 - 4 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 23 Dec 2022 Mersana Therapeutics and Merck to develop novel ADCs Mersana Therapeutics, Inc. has announced a research collaboration and commercial license agreement with a subsidiary of Merck KGaA, Darmstadt, Germany to discover novel Immunosynthen antibody drug conjugates (ADCs) directed against up to two targets. Immunosynthen, Mersana Therapeutics’ proprietary STING-agonist ADC platform, is designed to generate systemically administered ADCs that locally activate STING signaling in both […] December 23, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Dec 2022 Merck and Kelun-Biotech collaborating on seven ADC cancer candidates Merck (MSD outside of the U.S. and Canada), and Kelun-Biotech (a holding subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd), have entered into an exclusive license and collaboration agreement to develop seven investigational preclinical antibody-drug conjugates (ADC) for the treatment of cancer. “Advances in ADC technologies are yielding a new generation of candidates designed to more […] December 23, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 13 Oct 2022 Merck contributing to Jacobio Pharma colorectal cancer clinical trial Jacobio announced it has entered into a clinical trial collaboration agreement with Merck on a clinical study of combination therapy between Jacobio’s KRAS G12C inhibitor JAB-21822 and Merck’s epidermal growth factor receptor (EGFR) inhibitor Erbitux (cetuximab). This clinical study aims to evaluate the efficacy of JAB-21822 in combination with cetuximab in patients with KRAS G12C-mutated […] October 13, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 26 Sep 2022 TILT and MSD working on immunotherapy trial for non-small cell lung cancer TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapies, has signed a second clinical trial collaboration and supply agreement with MSD, a tradename of Merck & Co., Inc., Rahway, NJ, USA, for a new clinical trial evaluating TILT-123, its oncolytic adenovirus armed with two human cytokines, in combination with KEYTRUDA (pembrolizumab), MSD’s anti-PD-1 therapy. The […] September 26, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 12 Sep 2022 Astellas, Seagen and Merck give details on urothelial cancer treatment Astellas Pharma Inc., Seagen Inc. and Merck (known as MSD outside of the U.S. and Canada), have announced results from the phase 1b/2 EV-103 clinical trial (KEYNOTE-869) Cohort K investigating PADCEV (enfortumab vedotin-ejfv) in combination with Merck’s anti-PD-1 therapy KEYTRUDA (pembrolizumab) and PADCEV alone as first-line treatment in patients with unresectable locally advanced or metastatic […] September 12, 2022 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 8 Sep 2022 Investment of €130M made by Merck’s MilliporeSigma for life-saving therapies An investment of €130 million ($130 million) has been invested in Molsheim, France to strengthen manufacturing capabilities for single-use assemblies – a key technology for the production of Covid-19 vaccines and other life-saving therapies. The investment was made by MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA. It is the largest ever […] September 8, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email